Results 231 to 240 of about 54,678 (274)
Some of the next articles are maybe not open access.
EZH2 Inhibition as a Therapeutic Strategy for Lymphoma With EZH2-Activating Mutations
Nature, 2012In eukaryotes, post-translational modification of histones is critical for regulation of chromatin structure and gene expression. EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2) and is involved in repressing gene expression through methylation of histone H3 on lysine 27 (H3K27).
Michael T McCabe +2 more
exaly +3 more sources
EZH2 Inhibitors: The Unpacking Revolution
Cancer Research, 2022Abstract The methylation of lysine 27 on histone H3 (H3K27me3) is a chromatin mark associated with nucleosome condensation and gene expression silencing. EZH2 is a lysine methyltransferase that catalyzes H3K27me3. In this issue of Cancer Research, Porazzi and colleagues report that pretreatment with EZH2 inhibitors opened up the ...
Vera, Adema, Simona, Colla
openaire +2 more sources
Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
Oncogene, 2023Multiple myeloma (MM) is the second most common hematological malignancy with poor prognosis. Enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3) for transcriptional repression.
Xufen Yu +10 more
openaire +2 more sources
Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas
Blood, 2016Abstract EZH2 is critical in a process known as the Germinal Center (GC) reaction during which B-cells undergo somatic hypermutation and isotype switching in order to develop a large antibody repertoire. EZH2 is a histone methyltransferase serving as the catalytic subunit of the Polycomb Repression Complex 2 (PRC2), which is responsible ...
Jennifer Kimberly Lue +4 more
openaire +1 more source
Targeting EZH2 with tazemetostat
The Lancet Oncology, 2018Shinichi, Makita, Kensei, Tobinai
openaire +2 more sources
Science, 2012
A transcriptional repressor switches to an activator function in an aggressive form of prostate cancer.
openaire +1 more source
A transcriptional repressor switches to an activator function in an aggressive form of prostate cancer.
openaire +1 more source
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Cancer Cell, 2020Jun Jiang, Jun Qin, Minjia Tan
exaly
Mutant EZH2 Induces a Pre-Malignant Lymphoma Niche by Reprogramming the Immune Response
Cancer Cell, 2020Katsuyoshi Takata +2 more
exaly

